Eganelisib is under clinical development by Infinity Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Eganelisib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IPI-549 is under development for the treatment of solid tumors including metastatic renal cell cancer, soft tissue sarcoma and prostate cancer, triple negative breast cancer, colon cancer, metastatic melanoma, non-small cell lung cancer, glioblastoma multiforme, microsatellite-stable gallbladder carcinoma, head and neck cancer squamous cell carcinoma, mesothelioma, ovarian cancer, adrenocortical carcinoma and metastatic urothelial cancer including renal pelvis cancer, ureter cancer, bladder cancer, urethra cancer. The drug candidate is administered through oral route. It acts by targeting phosphoinositide-3-kinase gamma (PI3K-gamma). It was also under development for the treatment of metastatic ovarian cancer.
Infinity Pharmaceuticals overview
Infinity Pharmaceuticals is a biopharmaceutical company which discovers and develops small molecule therapeutics for the treatment of cancer. The company’s pipeline candidate: IPI-549 selectively inhibits PI3K-gamma to reprogram tumor-associated macrophages and transforms immuno-oncology approach. The company is evaluating IPI-549 as a monotherapy and in a combination therapy in various clinical trials for the treatment of various indications such advanced solid tumors, non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck (SCCHN), triple negative breast cancer (TNBC), mesothelioma, and myeloid-derived suppressor cells (MDSC). The company has collaborations with other biopharmaceuticals companies for the development of its pipeline programs. Infinity Pharmaceuticals is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Eganelisib’s drug-specific PTSR and LoA scores, buy the report here.